Back to News
Market Impact: 0.1
WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC Research and Development
Source: PR Newswire
Healthcare & Biotech
WuXi XDC Cayman Inc. (2268.HK), a global CRDMO focused on antibody-drug conjugates and other bioconjugates, issued a PRNewswire announcement from Shanghai on Sept. 17, 2026. The supplied article text is truncated before the substance of the announcement, so no financial, operational, or market-moving details can be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- BTIG cuts Acumen Pharmaceuticals stock price target to $1 on trial results
- Wells Fargo raises Abbvie stock price target to $340 on pipeline
- Wells Fargo raises Regeneron stock price target to $925 on execution
- Deutsche Bank downgrades Novartis stock rating to sell on valuation
- Apple, Marriott International and 3 Stocks to Watch Heading Into Monday